Certain Circumstances: ∘ “Bevacizumab .... and renal cell cancer carcinoma (HLRCC)- associated RCC ” was revised.
Search Results
NCCN Guidelines® Updates: Kidney Cancer
QIM20-124: Retrospective Evaluation of VEGF Inhibitor-Associated Hypertension at a Community Cancer Center
Jasmin Eugene, Carli Nesheiwat, and Scott Overmier
retrospective, single-center, chart review assessed patients’ blood pressure measurements who received bevacizumab, ramucirumab, sorafenib, regorafenib, sunitinib, or pazopanib. Patients were excluded if they were less than 18, received VEGF inhibitors for non
Current Evidence-Based Systemic Therapy for Advanced and Recurrent Endometrial Cancer
Sushmita Gordhandas, William A. Zammarrelli III, Eric V. Rios-Doria, Angela K. Green, and Vicky Makker
. Following frontline TC, the benefit of subsequent chemotherapy is modest, with a median PFS of 3 to 4 months and OS of 6 to 12 months. 1 The anti-VEGF antibody bevacizumab is also active in advanced EC as monotherapy and has been explored in combination
Challenges in the Management of Older Patients With Colon Cancer
Efrat Dotan, Ilene Browner, Arti Hurria, and Crystal Denlinger
metastatic colon cancer. The Use of Biologic Agents in the Older Population Bevacizumab The addition of the vascular endothelial growth factor antibody bevacizumab has been shown to improve progression-free and overall survivals among patients
Colon Cancer
Paul F. Engstrom, Juan Pablo Arnoletti, Al B. Benson III, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Anne Covey, Raza A. Dilawari, Dayna S. Early, Peter C. Enzinger, Marwan G. Fakih, James Fleshman Jr., Charles Fuchs, Jean L. Grem, Krystyna Kiel, James A. Knol, Lucille A. Leong, Edward Lin, Mary F. Mulcahy, Sujata Rao, David P. Ryan, Leonard Saltz, David Shibata, John M. Skibber, Constantinos Sofocleous, James Thomas, Alan P. Venook, and Christopher Willett
metastatic colorectal cancer treated with cetuximab . Ann Oncol 2008 ; 19 : 508 – 515 . 28 Punt CJ Tol J Rodenburg CJ . Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal
Moving Forward With Expanding to an “All-RAS Mutational Analysis” in Metastatic Colorectal Cancer: Beyond KRAS Mutations
Tanios Bekaii-Saab
] +/- panitumumab in first-line treatment of mCRC) suggests that the presence of these additional RAS mutations predict for lack of benefit. Data from the large phase II randomized study PEAK (FOLFOX plus panitumumab vs FOLFOX plus bevacizumab in first
Novel Non-Cytotoxic Therapy in Ovarian Cancer: Current Status and Future Prospects
Lainie Martin and Russell J. Schilder
. The safety of bevacizumab . Expert Opin Drug Saf 2006 ; 5 : 289 – 301 . 13. Jain RK . Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy . Nat Med 2001 ; 7 : 987 – 989 . 14
Value-Based Insurance Design: Aligning Incentives, Benefits, and Evidence in Oncology
Jonas A. de Souza, Mark J. Ratain, and A. Mark Fendrick
, bevacizumab is the same price per milligram for patients with metastatic colorectal cancer (5 mg/kg every 2 weeks), in whom it provides a median overall survival benefit of 4.7 months 16 (hazard ratio [HR] for death, 0.66; 95% CI, 0.54-0.81; P < .001), as
A “Shot Heard ’Round the World” on Cancer Drug Costs?
Harold J. Burstein
approval, MSKCC staff called the decision a “no brainer.” The median survival benefit with the drug was minimal (1.4 months); the drug has a similar mechanism of action to bevacizumab, which is already available for advanced colorectal cancer; and the drug
Updates in the Management of Hepatobiliary Cancers
Presented by: Mitesh J. Borad
,” commented Dr. Borad. Immunotherapy The combination of antiangiogenics with immune checkpoint inhibitors (atezolizumab + bevacizumab) is a recommended option for certain patients. “We know that hepatocellular cancers have a tumor microenvironment in a